by Michael May | Aug 22, 2023
The 10-year boom of the cell and gene therapy (CGT) industry has inevitably come to an end: public CGT valuations are way down, companies are settling into cash conservation mode, unrealistic salary demands are being replaced by layoffs, and the vultures circling with...
by David Kent | Aug 22, 2023
As an academic researcher in the blood stem cell field for the last 20 years, I’ve been involved in a large number of interdisciplinary collaborations and, more recently, a series of industry partnerships. There is no doubt in my mind that cell and gene therapy is one...
by Stephie Leung | Jul 20, 2023
A few months ago, I summarized seven local cell therapy companies in Canada that caught my attention. Since then, one full quarter of the financial calendar has passed. In the world of biotechnology start-ups, this could mean one more key milestone achieved, a new...
Comments